ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Revenue of ANI Pharmaceuticals, Inc. (ANIP)
Revenue in 2023 (TTM): $486.82 M
According to ANI Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $486.82 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of ANI Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $486.82 M | $305.3 M | $106.6 M | $19.87 M | $18.78 M |
| 2022 | $316.39 M | $177.6 M | $48.07 M | $-62,665,000 | $-47,896,000 |
| 2021 | $216.14 M | $115.53 M | $-1,684,000 | $-56,058,000 | $-42,603,000 |
| 2020 | $208.48 M | $121.32 M | $29.07 M | $-25,962,000 | $-22,548,000 |
| 2019 | $206.55 M | $143.39 M | $60.74 M | $3.16 M | $6.09 M |
| 2018 | $201.58 M | $128.55 M | $69.1 M | $20.05 M | $15.49 M |
| 2017 | $176.84 M | $97.81 M | $57.16 M | $16.35 M | $-1,076,000 |
| 2016 | $128.62 M | $79.84 M | $56.31 M | $8.68 M | $3.93 M |
| 2015 | $76.32 M | $63.63 M | $39.64 M | $21.73 M | $15.38 M |
| 2014 | $55.97 M | $44.5 M | $24.04 M | $19.38 M | $28.75 M |
| 2013 | $30.08 M | $20.11 M | $7.51 M | $126 K | $301 K |
| 2012 | $2.3 M | $-6,866,264 | $-27,232,565 | $-27,839,530 | $-27,717,739 |
| 2011 | $435.16 K | $385.16 K | $-50,778,691 | $-51,608,504,000 | $-51,608,504 |
| 2010 | $2.47 M | $2.21 M | $-45,340,146 | $-46,196,216,000 | $-46,196,216 |
| 2009 | $1.26 M | $1.26 M | $-47,243,463 | $-47,527,768,000 | $-47,527,768 |
| 2008 | $3.78 M | $3.78 M | $-17,382,041 | $-17,425,178,000 | $-17,425,178 |
| 2007 | $493.05 K | $493.05 K | $-7,494,611 | $-7,584,435,000 | $-7,584,435 |
| 2006 | $14.44 M | $14.44 M | $3.56 M | $2.79 B | $2.79 M |
| 2005 | $258.35 K | $258.35 K | $-9,550,098 | $-9,651,036,000 | $-9,651,036 |
| 2004 | $77.89 K | $77.89 K | $-11,914,264 | $-12,016,207 | $-12,016,207 |
| 2003 | $65.49 K | $65.49 K | $-5,953,016 | $-5,959,354 | $-5,959,354 |
| 2002 | $2.83 M | $2.83 M | $-3,718,591 | $-3,810,690 | $-3,810,690 |
| 2001 | $1.75 M | $1.75 M | $-2,675,217 | $-2,611,361 | $-2,611,361 |
| 2000 | $2 | $24.29 K | $-3,314,405 | $ | $-3,437,195 |
| 1999 | $1 | $1 | $-1,513,976 | $ | $-1,406,259 |
| 1998 | $123.06 K | $123.06 K | $-2,519,646 | $ | $-2,659,415 |